Patents Assigned to Immusol, Inc.
  • Publication number: 20050026172
    Abstract: Libraries for generating small interfering RNA (siRNA) are provided where the members of the library are optimized to inhibit the expression of genes that encode a predetermined family of proteins. The members of the library target at least mRNA encoding all members of the family of proteins. Methods for generating siRNA libraries of the present invention are also provided.
    Type: Application
    Filed: February 10, 2004
    Publication date: February 3, 2005
    Applicant: Immusol, Inc.
    Inventors: Henry Li, Jon Chatterton, Wufang Fan, Ning Ke, Flossie Wong-Staal
  • Publication number: 20040259079
    Abstract: The present invention provides a high complexity substantially complete hairpin ribozyme library having a randomized recognition sequence, packaged in a vector and operably linked to a promoter suitable for high level expression in a wide variety of cells. The invention comprises using the library in a variety of selection protocols for identifying, isolating and characterizing known or unknown target RNAs, to reveal the phenotypic effects of such cleavage, and to identify the gene products that produce those phenotypic effects.
    Type: Application
    Filed: July 22, 2004
    Publication date: December 23, 2004
    Applicant: Immusol, Inc.
    Inventors: Jack Barber, Peter Welch, Xinqiang Li, Richard Tritz
  • Patent number: 6808876
    Abstract: A method of identifying a compound that modulates the activity of a cellular regulator is provided. The method consists of contacting a sample containing a cellular regulator and a nucleic acid element acted on by the cellular regulator with a test compound under conditions that allow replication or expression of the nucleic acid element or a gene or mRNA operatively linked to the nucleic acid element or gene, and an increase or decrease in the amount of replication or expression in the presence of the test compound compared to the absence of the test compound indicates that the compound has cellular regulator modulatory activity. A method of treating a HCV infection is also provided.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: October 26, 2004
    Assignee: Immusol, Inc.
    Inventors: Martin Kruger, Peter J. Welch, Jack R. Barber
  • Patent number: 6787646
    Abstract: The invention provides substantially pure tumor suppressor nucleic acid molecules and tumor suppressor polypeptides. The invention also provides hairpin ribozymes and antibodies selective for these tumor suppressor molecules. Also provided are methods of detecting a neoplastic cell in a sample using detectable agents specific for the tumor suppressor nucleic acids and polypeptides.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: September 7, 2004
    Assignee: Immusol, Inc.
    Inventors: Peter J. Welch, Jack R. Barber
  • Patent number: 6770633
    Abstract: As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: August 3, 2004
    Assignee: Immusol, Inc.
    Inventors: Joan M. Robbins, Richard Tritz
  • Publication number: 20040146858
    Abstract: The present invention relates to methods and compositions for the elucidation of gene function and the identification of novel genes. Specifically, the present invention relates to methods and compositions for improved functional genomic screening, functional inactivation of specific essential or non-essential genes, and identification of genes that are modulated in response to specific stimuli or encode recognizable phenotypic traits. In particular, the compositions of the present invention include, but are not limited to, expression cassettes comprising a novel dual promoter transcription system, that utilizes modified promoters, preferably containing complementary termination sequences, positioned across a coding sequence and in opposite orientation to each other. In addition, the present invention includes libraries comprising the expression cassettes of the invention, including vectors for transforming cells, such as replication-deficient retroviral vectors.
    Type: Application
    Filed: July 23, 2003
    Publication date: July 29, 2004
    Applicant: Immusol, Inc.
    Inventors: Henry Li, Jon E. Chatterton, Ning Ke, Flossie Wong-Staal
  • Publication number: 20040115815
    Abstract: The present invention relates to methods and compositions for the elucidation of gene function and the identification of novel genes. Specifically, the present invention relates to methods and compositions for improved functional genomic screening, functional inactivation of specific essential or non-essential genes, and identification of genes that are modulated in response to specific stimuli or encode recognizable phenotypic traits. In particular, the compositions of the present invention include, but are not limited to, expression cassettes comprising a novel polymerase primer hairpin linker that allows rapid construction of a single transcriptional unit encoding both strands of a hairpin siRNA, regardless of sequence. In addition, the present invention includes libraries comprising the expression cassettes of the invention, including vectors for transforming cells, such as replication-deficient retroviral vectors.
    Type: Application
    Filed: July 23, 2003
    Publication date: June 17, 2004
    Applicant: Immusol, Inc.
    Inventors: Henry Li, Jon E. Chatterton, Ning Ke, Kristina L. Rhoades, Flossie Wong-Staal
  • Publication number: 20040071708
    Abstract: The present invention discloses compositions, systems and methods for identifying anti-cancer agents using doth in vitro and in vivo techniques. Embodiments include the screening of combinatorial libraries of peptides, antibodies, and small organic molecules as well as siRNAs, ribozymes and antisense nucleotides directed against nucleic acids encoding the GPR 39 protein.
    Type: Application
    Filed: September 26, 2002
    Publication date: April 15, 2004
    Applicant: Immusol, Inc.
    Inventors: Gisela Claassen, Henry Li, Jack Barber
  • Patent number: 6458567
    Abstract: This invention provides ribozymes useful to treat or prevent Hepatitis C Virus (“HCV”) infection or disease in an organism or subject, as well as methods of treating an HCV infection or disease. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes usefull in methods of treatment and prevention of HCV infection or disease are also provided.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: October 1, 2002
    Assignee: Immusol, Inc.
    Inventors: Jack R. Barber, Peter J. Welch, Richard Tritz, SoonPin Yei, Mang Yu
  • Patent number: 6043077
    Abstract: This invention provides ribozymes useful to treat or prevent Hepatitis C Virus ("HCV") infection or disease in an organism or subject, as well as methods of treating an HCV infection or disease. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes useful in methods of treatment and prevention of HCV infection or disease are also provided.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: March 28, 2000
    Assignee: Immusol Inc.
    Inventors: Jack R. Barber, Peter J. Welch, Richard Tritz, SoonPin Yei, Mang Yu